# Narration and storyboard draft: Multi-Cancer Blood Screening and Mortality

Authored draft, approximately 60–90 seconds; no rendered video claimed.

A blood test can find real cancer without yet proving that screening saves lives. Our review asks the precise question: does adding Galleri to usual care reduce cancer deaths in asymptomatic adults aged fifty and older? The latest NHS randomized report studied about142thousand people. Its primary combined stage-three-and-four endpoint did not improve. A secondary stage-four result was favorable, and that signal deserves follow-up, but neither result measures mortality. Prospective studies found genuine cancers and also false alarms requiring imaging and sometimes procedures. A large real-world series had clinical outcomes for fewer than half its positive tests, which limits broad accuracy claims. Other screening programmes show both possibilities: lung CT trials reduced deaths in selected high-risk smokers, while ovarian screening shifted stage without reducing mortality. HSEF Gamma therefore marks an unestablished mortality bridge, with high confidence in that evidence boundary. MRI and consumer genetic testing require their own benefit and harm studies. The decisive next result is randomized cancer-death follow-up, with interval cancers and diagnostic harms measured alongside it.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.